TY - JOUR
T1 - Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism
T2 - in vivo-detectable metabolic biomarkers of inhibition
AU - Nath, Kavindra
AU - Gupta, Pradeep K.
AU - Basappa, Johnvesly
AU - Wang, Shengchun
AU - Sen, Neil
AU - Lobello, Cosimo
AU - Tomar, Jyoti S.
AU - Shestov, Alexander A.
AU - Orlovskiy, Stepan
AU - Arias-Mendoza, Fernando
AU - Rauert-Wunderlich, Hilka
AU - Nelson, David S.
AU - Glickson, Jerry D.
AU - Wasik, Mariusz A.
N1 - Publisher Copyright:
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024.
PY - 2024/7/4
Y1 - 2024/7/4
N2 - Background: Inhibition of kinases is the ever-expanding therapeutic approach to various types of cancer. Typically, assessment of the treatment response is accomplished by standard, volumetric imaging procedures, performed weeks to months after the onset of treatment, given the predominantly cytostatic nature of the kinase inhibitors, at least when used as single agents. Therefore, there is a great clinical need to develop new monitoring approaches to detect the response to kinase inhibition much more promptly. Noninvasive 1H magnetic resonance spectroscopy (MRS) can measure in vitro and in vivo concentration of key metabolites which may potentially serve as biomarkers of response to kinase inhibition. Methods: We employed mantle cell lymphoma (MCL) cell lines demonstrating markedly diverse sensitivity of inhibition of Bruton’s tyrosine kinase (BTK) regarding their growth and studied in-depth effects of the inhibition on various aspects of cell metabolism including metabolite synthesis using metabolomics, glucose and oxidative metabolism by Seahorse XF technology, and concentration of index metabolites lactate, alanine, total choline and taurine by 1H MRS. Results: Effective BTK inhibition profoundly suppressed key cell metabolic pathways, foremost pyrimidine and purine synthesis, the citrate (TCA) cycle, glycolysis, and pyruvate and glutamine/alanine metabolism. It also inhibited glycolysis and amino acid-related oxidative metabolism. Finally, it profoundly and quickly decreased concentration of lactate (a product of mainly glycolysis) and alanine (an indicator of amino acid metabolism) and, less universally total choline both in vitro and in vivo, in the MCL xenotransplant model. The decrease correlated directly with the degree of inhibition of lymphoma cell expansion and tumor growth. Conclusions: Our results indicate that BTK inhibition exerts a broad and profound suppressive effect on cell metabolism and that the affected index metabolites such as lactate, alanine may serve as early, sensitive, and reliable biomarkers of inhibition in lymphoma patients detectable by noninvasive MRS-based imaging method. This kind of imaging-based detection may also be applicable to other kinase inhibitors, as well as diverse lymphoid and non-lymphoid malignancies.
AB - Background: Inhibition of kinases is the ever-expanding therapeutic approach to various types of cancer. Typically, assessment of the treatment response is accomplished by standard, volumetric imaging procedures, performed weeks to months after the onset of treatment, given the predominantly cytostatic nature of the kinase inhibitors, at least when used as single agents. Therefore, there is a great clinical need to develop new monitoring approaches to detect the response to kinase inhibition much more promptly. Noninvasive 1H magnetic resonance spectroscopy (MRS) can measure in vitro and in vivo concentration of key metabolites which may potentially serve as biomarkers of response to kinase inhibition. Methods: We employed mantle cell lymphoma (MCL) cell lines demonstrating markedly diverse sensitivity of inhibition of Bruton’s tyrosine kinase (BTK) regarding their growth and studied in-depth effects of the inhibition on various aspects of cell metabolism including metabolite synthesis using metabolomics, glucose and oxidative metabolism by Seahorse XF technology, and concentration of index metabolites lactate, alanine, total choline and taurine by 1H MRS. Results: Effective BTK inhibition profoundly suppressed key cell metabolic pathways, foremost pyrimidine and purine synthesis, the citrate (TCA) cycle, glycolysis, and pyruvate and glutamine/alanine metabolism. It also inhibited glycolysis and amino acid-related oxidative metabolism. Finally, it profoundly and quickly decreased concentration of lactate (a product of mainly glycolysis) and alanine (an indicator of amino acid metabolism) and, less universally total choline both in vitro and in vivo, in the MCL xenotransplant model. The decrease correlated directly with the degree of inhibition of lymphoma cell expansion and tumor growth. Conclusions: Our results indicate that BTK inhibition exerts a broad and profound suppressive effect on cell metabolism and that the affected index metabolites such as lactate, alanine may serve as early, sensitive, and reliable biomarkers of inhibition in lymphoma patients detectable by noninvasive MRS-based imaging method. This kind of imaging-based detection may also be applicable to other kinase inhibitors, as well as diverse lymphoid and non-lymphoid malignancies.
KW - ACP-196 (acalabrutinib)
KW - Bruton’s tyrosine kinase (BTK)
KW - Ibrutinib (IBR)
KW - Magnetic resonance spectroscopy (MRS)
KW - Mantle cell lymphoma (MCL)
KW - Proton magnetic resonance spectroscopy (H MRS)
KW - RNA Sequence analysis (RNA-Seq)
KW - Signaling inhibition
KW - Tricarboxylic or Citric acid cycle (TCA)
KW - Humans
KW - Biomarkers/metabolism
KW - Signal Transduction/drug effects
KW - Xenograft Model Antitumor Assays
KW - Animals
KW - Cell Line, Tumor
KW - Agammaglobulinaemia Tyrosine Kinase/metabolism
KW - Mice
KW - Protein Kinase Inhibitors/pharmacology
KW - Cell Proliferation/drug effects
KW - Lymphoma, Mantle-Cell/metabolism
KW - Biomarkers, Tumor/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85197479786&partnerID=8YFLogxK
U2 - 10.1186/s12967-024-05371-9
DO - 10.1186/s12967-024-05371-9
M3 - Article
C2 - 38965536
AN - SCOPUS:85197479786
SN - 1479-5876
VL - 22
SP - 622
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 622
ER -